GlassScriptPhysician profile
Dara Ratliff
NPI 1265162010
$991.92
in general payments reported to CMS, 2019-2025
23 companies · $528 in 2025
The $528 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $316 · 2024: $147 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.94 |
| Education | $351.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151.18 | 2024-2025 | |
| Janssen Biotech, INC. | $129.63 | 2023-2025 | Darzalex, Rybrevant |
| Pharmacyclics LLC, An Abbvie Company | $98.00 | 2023 | Imbruvica |
| Shield Therapeutics INC | $91.68 | 2024 | |
| Astellas Pharma US INC | $72.83 | 2025 | Padcev, Vyloy |
| Daiichi Sankyo INC. | $63.41 | 2025 | Datroway |
| Lilly USA, LLC | $44.93 | 2023-2025 | Verzenio, Jaypirca |
| Novartis Pharmaceuticals Corporation | $38.48 | 2024-2025 | |
| Pharmaessentia USA Corporation | $33.62 | 2025 | Besremi |
| Merck Sharp & Dohme LLC | $25.53 | 2025 | Welireg, Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.11 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.34 | 2025 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $21.33 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2025 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $19.96 | 2023 | |
| Eisai INC. | $17.59 | 2025 | |
| Celgene Corporation | $17.22 | 2025 | Reblozyl |
| Servier Pharmaceuticals LLC | $16.23 | 2025 | |
| Mylan Institutional INC. | $16.22 | 2023 | Fulphila, Ogivri |
| Gilead Sciences, INC. | $14.85 | 2023 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $14.80 | 2025 | |
| Pfizer INC. | $14.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Ratliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.